Cynosure, Inc. (NASDAQ:CYNO) – Research analysts at Leerink Swann issued their FY2018 earnings estimates for shares of Cynosure in a report released on Wednesday. Leerink Swann analyst R. Newitter anticipates that the firm will post earnings of $1.95 per share for the year. Leerink Swann has a “Outperform” rating and a $60.00 price objective on the stock.
Cynosure (NASDAQ:CYNO) last posted its quarterly earnings results on Tuesday, February 7th. The company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.41 by $0.03. The business earned $122.10 million during the quarter, compared to analysts’ expectations of $119.97 million. Cynosure had a return on equity of 6.86% and a net margin of 3.56%. The company’s quarterly revenue was up 19.2% compared to the same quarter last year. During the same period last year, the firm earned $0.42 EPS.
Several other analysts have also recently issued reports on the company. Northcoast Research cut Cynosure from a “buy” rating to a “sell” rating and set a $40.00 price objective on the stock. in a research note on Friday, January 6th. Brean Capital restated a “buy” rating on shares of Cynosure in a research note on Monday, October 24th. Zacks Investment Research lowered Cynosure from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 19th. TheStreet lowered Cynosure from a “buy” rating to a “hold” rating in a report on Wednesday, November 16th. Finally, Northland Securities set a $60.00 target price on Cynosure and gave the company a “buy” rating in a report on Monday, January 23rd. Two research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $57.88.
Cynosure (NASDAQ:CYNO) traded up 1.19% during mid-day trading on Friday, hitting $55.05. The stock had a trading volume of 974,926 shares. Cynosure has a 12-month low of $34.47 and a 12-month high of $55.94. The company has a 50-day moving average of $47.51 and a 200-day moving average of $48.44. The stock has a market cap of $1.30 billion, a price-to-earnings ratio of 84.69 and a beta of 1.65.
In related news, Chairman Michael R. Davin sold 16,284 shares of the stock in a transaction that occurred on Tuesday, November 22nd. The stock was sold at an average price of $45.00, for a total value of $732,780.00. Following the completion of the transaction, the chairman now directly owns 4,222 shares of the company’s stock, valued at approximately $189,990. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Douglas J. Delaney sold 7,875 shares of the stock in a transaction that occurred on Tuesday, November 22nd. The stock was sold at an average price of $45.00, for a total value of $354,375.00. Following the completion of the transaction, the vice president now directly owns 5,833 shares of the company’s stock, valued at $262,485. The disclosure for this sale can be found here. Corporate insiders own 2.90% of the company’s stock.
Institutional investors have recently modified their holdings of the stock. Quantbot Technologies LP raised its position in shares of Cynosure by 223.1% in the third quarter. Quantbot Technologies LP now owns 2,982 shares of the company’s stock worth $151,000 after buying an additional 2,059 shares during the last quarter. Teacher Retirement System of Texas raised its position in shares of Cynosure by 27.8% in the second quarter. Teacher Retirement System of Texas now owns 3,209 shares of the company’s stock worth $156,000 after buying an additional 699 shares during the last quarter. Acrospire Investment Management LLC raised its position in shares of Cynosure by 18.3% in the third quarter. Acrospire Investment Management LLC now owns 3,239 shares of the company’s stock worth $165,000 after buying an additional 500 shares during the last quarter. Campbell & CO Investment Adviser LLC purchased a new position in shares of Cynosure during the third quarter worth about $200,000. Finally, Suntrust Banks Inc. raised its position in shares of Cynosure by 0.8% in the third quarter. Suntrust Banks Inc. now owns 4,373 shares of the company’s stock worth $222,000 after buying an additional 36 shares during the last quarter.
Cynosure Company Profile
Cynosure Inc (Cynosure) develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve gynecologic health.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/research-analysts-set-expectations-for-cynosure-inc-s-fy2018-earnings-cyno/1655929.html
Receive News & Ratings for Cynosure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynosure Inc. and related companies with MarketBeat.com's FREE daily email newsletter.